Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | KCNQ4 | P56696 | 4/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25829281 | 0.84 | CYP17A1 (0.43) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL29549489 | 0.79 | HDAC1 (0.50) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL6578598 | 0.79 | HDAC1 (0.38) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL29581478 | 0.79 | HDAC1 (0.55) | CYP17A1KCNQ4KCNQ5AAK1KCNQ3 | |
| SCHEMBL826795 | 0.79 | HDAC1 (0.50) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 | |
| SCHEMBL197145 | 0.79 | HDAC1 (0.55) | CYP17A1KCNQ4KCNQ5AAK1KCNQ3 | |
| SCHEMBL22874399 | 0.79 | HDAC1 (0.50) | CYP17A1KCNQ4KCNQ5RXFP1LMNA | |
| SCHEMBL15614546 | 0.78 | MAPT (0.51) | CYP17A1KCNQ4KCNQ5RXFP1LMNA | |
| SCHEMBL857284 | 0.78 | HTT (0.55) | CYP17A1KCNQ4KCNQ5LMNAPOLB | |
| SCHEMBL197226 | 0.78 | AAK1 (0.43) | CYP17A1KCNQ4KCNQ5RXFP1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| CN-102459159-A | Alkanoylamino benzamide aniline hdac inihibitor compounds | GILEAD COLORADO INC | 2012-05-16 | — | — | CN | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | CYP17A1 1381/4885KCNQ4 3579/4885KCNQ5 2888/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | CYP17A1 1381/4885KCNQ4 3579/4885KCNQ5 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.